A new pharmacology study evaluating a high-CBD cannabis extract produced through supercritical CO2 extraction reports notable reductions in inflammation and pain responses, adding to growing evidence that cannabis extracts have meaningful therapeutic value.

Researchers analyzed the extract, derived from the CIM-CS-64 genotype, using a full suite of chemical profiling tools. The team identified 62 compounds, with cannabidiol, β-caryophyllene, cannabidivarin, cannabichromene, (E)-phytol, and α-bisabolol among the primary constituents. Further testing confirmed measurable levels of CBD at 9.75%, CBDA at 2.76%, and delta-9 THC at 4.40%.

In laboratory testing, the extract significantly reduced two key pro-inflammatory cytokines—TNF-α and IL-6—in LPS-stimulated macrophages. Those reductions were observed at concentrations of 3, 10, and 30 micrograms per milliliter, with no signs of cytotoxicity at any dose. The extract also produced meaningful improvements in pain-related behaviors, with effects increasing as doses rose.

According to the authors, the findings indicate that this CO2-derived extract has a clear analgesic and anti-inflammatory profile in small animal models.

While further research is needed to determine how these outcomes may translate to humans, the study provides additional evidence that targeted high-CBD extractions may offer therapeutic benefits for pain and inflammatory conditions without compromising cell viability.